PL2999711T3 - Pochodne polimyksyny i ich zastosowanie w terapii skojarzonej razem z różnymi antybiotykami - Google Patents

Pochodne polimyksyny i ich zastosowanie w terapii skojarzonej razem z różnymi antybiotykami

Info

Publication number
PL2999711T3
PL2999711T3 PL14726731.4T PL14726731T PL2999711T3 PL 2999711 T3 PL2999711 T3 PL 2999711T3 PL 14726731 T PL14726731 T PL 14726731T PL 2999711 T3 PL2999711 T3 PL 2999711T3
Authority
PL
Poland
Prior art keywords
combination therapy
various antibiotics
therapy together
polymyxin derivatives
polymyxin
Prior art date
Application number
PL14726731.4T
Other languages
English (en)
Inventor
Pamela Brown
Michael Dawson
Mona SIMONOVIC
Steven Boakes
Esther DUPERCHY
Original Assignee
Spero Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201309248A external-priority patent/GB201309248D0/en
Priority claimed from GB201404301A external-priority patent/GB201404301D0/en
Application filed by Spero Therapeutics, Inc. filed Critical Spero Therapeutics, Inc.
Publication of PL2999711T3 publication Critical patent/PL2999711T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/60—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation occurring through the 4-amino group of 2,4-diamino-butanoic acid
    • C07K7/62—Polymyxins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL14726731.4T 2013-05-22 2014-05-21 Pochodne polimyksyny i ich zastosowanie w terapii skojarzonej razem z różnymi antybiotykami PL2999711T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201309248A GB201309248D0 (en) 2013-05-22 2013-05-22 Compounds and combinations
GB201404301A GB201404301D0 (en) 2014-03-11 2014-03-11 Compounds and combinations
PCT/GB2014/051547 WO2014188178A1 (en) 2013-05-22 2014-05-21 Polymyxin derivatives and their use in combination therapy together with different antibiotics

Publications (1)

Publication Number Publication Date
PL2999711T3 true PL2999711T3 (pl) 2022-09-26

Family

ID=50829204

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14726731.4T PL2999711T3 (pl) 2013-05-22 2014-05-21 Pochodne polimyksyny i ich zastosowanie w terapii skojarzonej razem z różnymi antybiotykami

Country Status (20)

Country Link
US (1) US10407467B2 (pl)
EP (1) EP2999711B1 (pl)
JP (1) JP6643758B2 (pl)
KR (1) KR102354902B1 (pl)
CN (1) CN105308065B (pl)
BR (1) BR112015029309A2 (pl)
CA (1) CA2939061C (pl)
CY (1) CY1125479T1 (pl)
DK (1) DK2999711T3 (pl)
ES (1) ES2923762T3 (pl)
HR (1) HRP20220898T1 (pl)
HU (1) HUE059544T2 (pl)
LT (1) LT2999711T (pl)
PL (1) PL2999711T3 (pl)
PT (1) PT2999711T (pl)
RS (1) RS63484B1 (pl)
RU (1) RU2730012C2 (pl)
SI (1) SI2999711T1 (pl)
TW (1) TWI665218B (pl)
WO (1) WO2014188178A1 (pl)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX355217B (es) 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
EP3038615A4 (en) * 2013-08-28 2017-04-12 The Medicines Company Methods for treating bacterial infections using oritavancin and polymyxins
KR20160135739A (ko) * 2014-03-11 2016-11-28 뉴 파마 라이센스 홀딩스 리미티드 폴리믹신 유도체 및 상이한 항생제와의 조합 요법에 있어서의 이들의 용도
CN107108699A (zh) 2014-11-26 2017-08-29 新药物许可控股有限公司 化合物
EP3233889B1 (en) * 2014-12-16 2022-07-06 Shanghai MicuRx Pharmaceutical Co., Ltd. Antimicrobial polymyxins for treatment of bacterial infections
FI126143B (en) 2015-01-15 2016-07-15 Northern Antibiotics Oy Polymyxine derivative and its uses
US9763996B2 (en) 2015-01-16 2017-09-19 Northern Antibiotics, Ltd. Polymyxin derivative and uses thereof
KR101790296B1 (ko) * 2015-03-26 2017-10-26 한국생명공학연구원 네트롭신을 유효성분으로 포함하는 그람음성 세균에 대한 폴리믹신의 항균 활성을 증가시키는 조성물
WO2016166103A1 (en) * 2015-04-13 2016-10-20 Xellia Pharmaceuticals Aps Polymyxin derivatives
JP7367950B2 (ja) * 2015-09-29 2023-10-24 モナッシュ ユニバーシティ 抗菌性ポリミキシン誘導体化合物
CN109789125B (zh) * 2016-08-16 2022-10-18 罗切斯特大学 含有基于多粘菌素b/甲氧苄啶的治疗剂的药物组合物
CN106631902A (zh) * 2016-09-23 2017-05-10 上海步越化工科技有限公司 一种特拉万星侧链癸基(2‑氧代乙基)氨基甲酸9h‑芴‑9‑甲基酯的制备方法
US11191773B2 (en) 2017-07-17 2021-12-07 President And Fellows Of Harvard College Methods of treatment for bacterial infections
CN111247162B (zh) * 2017-10-31 2022-02-18 正大天晴药业集团股份有限公司 多黏菌素类似物及其制备方法
WO2019084628A1 (en) 2017-11-02 2019-05-09 The University Of Queensland Peptide antibiotics
US11713335B2 (en) 2018-03-12 2023-08-01 President And Fellows Of Harvard College Aminocoumarin compounds and methods of their use
DK3810633T3 (da) 2018-06-25 2024-01-15 Spero Therapeutics Inc Forbindelser
CN111690040A (zh) * 2019-03-12 2020-09-22 上海来益生物药物研究开发中心有限责任公司 多粘菌素衍生物、其制备方法和应用
CN110179967A (zh) * 2019-05-28 2019-08-30 中国医药集团总公司四川抗菌素工业研究所 多粘菌素母核和一种抗生素的组合物及其应用
WO2021150792A1 (en) 2020-01-21 2021-07-29 Micurx Pharmaceuticals, Inc. Novel compounds and composition for targeted therapy of kidney-associated cancers
US20220395555A1 (en) * 2020-06-11 2022-12-15 Boris Farber Derivatives of antibiotics
US12472195B2 (en) 2020-07-02 2025-11-18 Purdue Research Foundation Inhalation formulations of antimicrobial compounds
TW202233649A (zh) 2020-11-06 2022-09-01 美商斯佩羅治療學股份有限公司 化合物
CN116847735B (zh) * 2021-02-02 2026-02-03 韩国生命工学研究院 含有联苯基衍生物化合物作为有效成分的抗菌佐剂及其用途
WO2023283256A1 (en) 2021-07-09 2023-01-12 Aligos Therapeutics, Inc. Anti-viral compounds
US12065428B2 (en) 2021-09-17 2024-08-20 Aligos Therapeutics, Inc. Anti-viral compounds
WO2024003042A1 (en) 2022-06-28 2024-01-04 Breakthrough Biotech Drift Aps Novel combinations of sesquiterpene alcohols, polymyxins and nisin compounds as antimicobial and/or antifungal compounds
AU2023303408A1 (en) 2022-07-06 2024-12-19 Aligos Therapeutics, Inc. Anti-viral compounds
EP4611762A1 (en) * 2022-11-14 2025-09-10 Cipla Limited Novel ophthalmic composition
KR102952821B1 (ko) * 2022-11-23 2026-04-16 웰펩 주식회사 폴리믹신 e 및 폴리믹신 b의 제조방법
CN116212004A (zh) * 2022-12-07 2023-06-06 东南大学 一种复合抗生素吸入用粉剂及其制备方法与应用
IL326320A (en) * 2023-08-03 2026-04-01 Arcum Vision Inc Enhanced formulation of polymyxin b/ trimethoprim and rifampin and methods for ophthalmic uses
KR20250037611A (ko) * 2023-09-07 2025-03-18 웰펩 주식회사 그람 음성균 및 다제내성 그람 음성균에 우수한 항균 활성을 갖는 신규 폴리믹신 유사체, 이를 포함하는 항균용 조성물
WO2025236916A1 (en) * 2024-05-16 2025-11-20 Brii Biosciences, Inc. Compositions and methods for treating infections

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2128617A (en) 1982-10-06 1984-05-02 Martti Vaara Polypeptides for use in antibacterial therapy
AU7753787A (en) 1986-08-06 1988-02-24 Jean-Luc Fauchere Production of covalent-linked conjugates from an antibiotic and a non-toxic derivative of polymyxine b
US20010021697A1 (en) 1987-09-14 2001-09-13 Henning Lowenstein Methods and compositions for the treatment of mammalian infections employing medicaments comprising hymenoptera venom, proteinageous or polypeptide components thereof, or analogues of such proteinaceous or polypeptide components
TW274552B (pl) 1992-05-26 1996-04-21 Hoechst Ag
US5767068A (en) 1997-02-13 1998-06-16 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
JP4583559B2 (ja) * 2000-07-24 2010-11-17 栄研化学株式会社 Ｍｒｓａスクリーニング用培地
JP2007507512A (ja) 2003-09-30 2007-03-29 コーヒ コーポレーション 熱傷を治療するための組成物および方法
US20060004185A1 (en) 2004-07-01 2006-01-05 Leese Richard A Peptide antibiotics and peptide intermediates for their prepartion
WO2008001773A1 (fr) 2006-06-27 2008-01-03 Toyo Tire & Rubber Co., Ltd. pneu apte à rouler dégonflé
BRPI0715095B8 (pt) * 2006-08-11 2021-05-25 Northern Antibiotics Oy derivado de polimixina da fórmula geral (i); produto de combinação; composição farmacêutica; método para se sensibilizar bactérias gram-negativas a um agente antibacteriano; método para o desenvolvimento de antibióticos; método para a redução da toxicidade de polimixinas, octapeptinas naturais e seus derivados durante a aplicação das mesmas no tratamento de infecções em um indivíduo; método para melhorar as propriedades farmacocinéticas, de polimixinas, octapeptinas naturais e seus derivados; método para a sensibilização de bactérias gram-negativas clinicamente importantes a um complemento de mecanismo de defesa presente no soro; uso de um derivado; e processo para a preparação de um derivado de polimixina da fórmula (i).
US8193148B2 (en) 2008-02-08 2012-06-05 Northern Antibiotics Ltd. Short fatty acid tail polymyxin derivatives and uses thereof
US8329645B2 (en) 2008-02-08 2012-12-11 Northern Antibiotics Ltd. Polymyxin derivatives and uses thereof
FI20085469A0 (fi) * 2008-02-08 2008-05-16 Northern Antibiotics Oy Polymyksiinijohdannaiset, joissa on lyhyt rasvahappohäntä, ja niiden käyttöjä
ES2334547B1 (es) 2008-09-10 2010-12-03 Universidad De Barcelona Compuestos peptidicos antibacterianos.
WO2010075416A1 (en) 2008-12-23 2010-07-01 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
JP5493387B2 (ja) * 2009-02-25 2014-05-14 国立大学法人 東京大学 選択培地の製造方法及びその利用
CN101851270A (zh) 2009-04-03 2010-10-06 梁浩 一种多粘菌素衍生物及其制备方法
WO2010130007A1 (en) 2009-05-14 2010-11-18 Monash University Antimicrobial compounds
US8415307B1 (en) 2010-06-23 2013-04-09 Biosource Pharm, Inc. Antibiotic compositions for the treatment of gram negative infections
WO2012051663A1 (en) 2010-10-21 2012-04-26 Monash University Antimicrobial compounds
US9226786B2 (en) * 2011-03-22 2016-01-05 Lexion Medical Llc Medical devices for clearing a surgical site
WO2012168820A1 (en) 2011-06-08 2012-12-13 Pfizer Inc. Polymyxin derivatives useful as antibacterial agents
MX355217B (es) * 2011-11-18 2018-04-10 New Pharma Licence Holdings Ltd Derivados de polimixina.
HUE059544T2 (hu) 2013-05-22 2022-11-28 Spero Therapeutics Inc Polimixin-származékok és ezek alkalmazása kombinációs terápiában különbözõ antibiotikumokkal
US10047126B2 (en) 2014-04-01 2018-08-14 Monash University Polymyxin derivatives as antimicrobial compounds

Also Published As

Publication number Publication date
HUE059544T2 (hu) 2022-11-28
PT2999711T (pt) 2022-07-29
US10407467B2 (en) 2019-09-10
CA2939061A1 (en) 2014-11-27
CN105308065B (zh) 2021-10-15
CA2939061C (en) 2023-10-24
KR20160009041A (ko) 2016-01-25
SI2999711T1 (sl) 2022-10-28
HK1221474A1 (en) 2017-06-02
DK2999711T3 (da) 2022-07-18
EP2999711B1 (en) 2022-06-29
TW201444876A (zh) 2014-12-01
KR102354902B1 (ko) 2022-01-24
HRP20220898T1 (hr) 2022-10-14
WO2014188178A9 (en) 2015-01-08
JP2016527186A (ja) 2016-09-08
RU2015148032A (ru) 2017-06-27
JP6643758B2 (ja) 2020-02-12
EP2999711A1 (en) 2016-03-30
CN105308065A (zh) 2016-02-03
US20160222061A1 (en) 2016-08-04
TWI665218B (zh) 2019-07-11
CY1125479T1 (el) 2026-02-25
LT2999711T (lt) 2022-09-12
RS63484B1 (sr) 2022-09-30
RU2730012C2 (ru) 2020-08-14
ES2923762T3 (es) 2022-09-30
WO2014188178A1 (en) 2014-11-27
BR112015029309A2 (pt) 2017-07-25

Similar Documents

Publication Publication Date Title
CY1125479T1 (el) Παραγωγα πολυμυξινης και η χρηση αυτων σε πολυθεραπεια μαζι με διαφορα αντιβιοτικα
IL241409B (en) Mirna biogenesis in exosomes for diagnosis and therapy
IL242610A0 (en) History of pyrazolopyrrolidine and their use in the treatment of diseases
SI3043784T1 (sl) Aril etri in njihova uporaba
PL3542798T3 (pl) Aceklidyna do zastosowania w leczeniu starczowzroczności
DK3083616T3 (da) Bicykliske heterocykliske forbindelser og disses anvendelser i terapi
HRP20181392T1 (hr) Heterociklični spojevi i njihova uporaba
LT2970303T (lt) Pakeistieji ksantinai ir jų panaudojimo metodai
IL247243B (en) Polymyxin history and their use in combination therapy together with different antibiotics
DK3065759T3 (da) Immunosuppressive midler og deres anvendelse i terapi
EP2882027A4 (en) Electrode assembly and basic unit body for same
PL3004112T3 (pl) Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby
IL243728B (en) Indole derivatives as rorc2 inhibitors and uses thereof
BR112016004943A2 (pt) aparelho médico e uso
PL2988750T5 (pl) Zastosowanie chlorowodorku landilolu w długotrwałym leczeniu tachyarytmii
DK3087076T3 (da) Imidazopyrazinonderivater
BR112015023621A8 (pt) derivados de meropenem e suas utilizações
GB201308753D0 (en) Compounds and their use in therapy
FR3007291B1 (fr) Composition cicatrisante et utlisation
PL3027208T3 (pl) Diagnoza i terapia nowotworu z udziałem nowotworowych komórek macierzystych
GB201308217D0 (en) Compounds and their use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB201312131D0 (en) Drug combination and its use in therapy
GB201312129D0 (en) Drug combination and its use in therapy
FI20135142L (fi) Lyhtypylväs ja sovitelma lyhtypylvääseen